| 764278 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
726 Tumor Treating Fields (TTFields) induce an altered polarization program in M1/M2 macrophages |
2021-11-01 |
10.1136/jitc-2021-sitc2021.726 |
Barsheshet Yiftah, Brant Boris, Voloshin Tali, Volodin Alexandra, Koren Lilach, Klein-Goldberg Anat, Zemer-Tov Efrat, Paz Rom, Giladi Moshe, Weinberg Uri, Palti Yoram |
| 764277 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
725 Immunomodulation by targeting PDL-1 in colon cancer using nuclear receptor 4A1 (NR4A1) antagonists |
2021-11-01 |
10.1136/jitc-2021-sitc2021.725 |
Abdelrahim Maen, Mohankumar Kumaravel, Karki Keshav, Safe Stephen |
| 764276 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
724 Evaluation of an anti-human IL-1β antibody in monosodium urate crystals-induced peritonitis model in hIL-1β HuGEMM™ mice |
2021-11-01 |
10.1136/jitc-2021-sitc2021.724 |
An Xiaoyu, Lian Kaixia, Zheng Jia, Jian Fei, Li Henry, Yang Tao |
| 764275 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
576 Tumor Targeted Superantigen (TTS), Naptumomab Estafenatox (NAP), enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.576 |
Sagi Yael, Shahar Michal, Pinsker Marina |
| 764274 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
573 FS120, an OX40/CD137 tetravalent bispecific dual agonist antibody, synergistically increases the antitumor activity of anti-PD-1 in preclinical studies |
2021-11-01 |
10.1136/jitc-2021-sitc2021.573 |
Lakins Matthew, Liao Wenjia, McConnell Emma, Kaka Quincy, Ofoedu Jennifer, Gradinaru Cristian, Giambalvo Raffaella, Gaspar Miguel, Poon Edmund, Morrow Michelle, Brewis Neil |
| 764273 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
572 Combination therapy of exoSTING, exoIL-12 activates systemic anti-tumor immunity |
2021-11-01 |
10.1136/jitc-2021-sitc2021.572 |
Kirwin Katherine, Jang Su Chul, Sia Christine, Dooley Kevin, Zi Tong, Zhang Kelvin, Liu Yanyan, Economides Kyriakos, Patel Shil, Sathyanaryanan Sriram |
| 764272 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
569 A novel microbiome-derived peptide reverses resistance to anti-PD-1 therapy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.569 |
Haria Dhwani, Ravichandar Jayamary Divya, Desnoyer Jill, Lau Sabina, Lee Jina, Rutherford Erica, Lal Preeti, Dabbagh Karim, Kiefel Helena |
| 764271 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
568 Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking T-lymphocyte recruitment |
2021-11-01 |
10.1136/jitc-2021-sitc2021.568 |
Haake Markus, Schäfer Tina, Haack Beatrice, Vashist Neha, Genßler Sabrina, Harter Patrick, Martens Alexander, Wistuba-Hamprecht Kilian, Wedekink Florian, Fischer Birgitt, Mittelbronn Michel, Levesque Mitchell, Cheng Phil, Dummer Reinhard, Weide Benjamin, Klar Kathrin, Leo Eugen, Nimmerjahn Falk, Schuberth-Wagner Christine, Wischhusen Jörg |
| 764270 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
566 ATOR-1017, a second generation 4–1BB antibody with potential to enhance efficacy of PD-1 therapies |
2021-11-01 |
10.1136/jitc-2021-sitc2021.566 |
Smith Karin Enell, Nilsson Anneli, Ellmark Peter |
| 764269 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
565 Combinatorial HSCs and anti-PD-1 therapy in microsatellite stable colorectal cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.565 |
Dean Bayli DiVita, Figg John, Font Laura Falceto, Francis Connor, Mitchell Duane, Flores Catherine |
